Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert James Gray, Ph.D.

Title
Institution
Department
Address
Phone
Profile Picture

Overview

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U01CA233169 (GRAY, ROBERT J) Sep 18, 2018 - Aug 31, 2023
    NIH
    Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
    Role: Principal Investigator
  2. U10CA180794 (GRAY, ROBERT J) Apr 29, 2014 - Feb 28, 2025
    NIH
    ECOG-ACRIN Network Group Statistics and Data Management Center
    Role: Co-Principal Investigator
  3. U10CA066636 (GRAY, ROBERT J) Aug 5, 1994 - Apr 30, 2016
    NIH
    ECOG Statistical Office Data Management Grant
    Role: Principal Investigator
  4. R01CA057253 (GRAY, ROBERT J) Jul 1, 1992 - Nov 30, 2003
    NIH
    MODELING FAILURE TIME DATA IN CANCER RESEARCH
    Role: Principal Investigator
  5. U10CA023318 (GRAY, ROBERT J) Mar 1, 1978 - Apr 30, 2016
    NIH
    ECOG Statistical Office
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Meric-Bernstam F, Ford JM, O'Dwyer PJ, Shapiro GI, McShane LM, Freidlin B, O'Cearbhaill RE, George S, Glade Bender J, Lyman GH, Tricoli JV, Patton D, Hamilton SR, Gray RJ, Hawkins DS, Ramineni B, Flaherty KT, Grivas P, Yap TA, Berlin J, Doroshow JH, Harris LN, Moscow JA. National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH). Clin Cancer Res. 2023 Jan 20. PMID: 36662819.
    Citations:    Fields:    
  2. Unger JM, LeBlanc M, George S, Wolmark N, Curran WJ, O'Dwyer PJ, Schnall MD, Mannel RS, Mandrekar SJ, Gray RJ, Zhao F, Bah M, Vaidya R, Blanke CD. Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies. J Clin Oncol. 2022 Dec 08; JCO2201826. PMID: 36480773.
    Citations:    Fields:    
  3. Bedard PL, Li S, Wisinski KB, Yang ES, Limaye SA, Mitchell EP, Zwiebel JA, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B. JCO Precis Oncol. 2022 07; 6:e2200165. PMID: 35939768; PMCID: PMC9384949.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  4. Sadigh G, Gray RJ, Sparano JA, Yanez B, Garcia SF, Timsina LR, Obeng-Gyasi S, Gareen I, Sledge GW, Whelan TJ, Cella D, Wagner LI, Carlos RC. Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Oncol. 2022 04 01; 8(4):579-586. PMID: 35175284; PMCID: PMC8855314.
    Citations:    Fields:    Translation:Humans
  5. Obeng-Gyasi S, Graham N, Kumar S, Lee JW, Jacobus S, Weiss M, Cella D, Zhao F, Ip EH, O'Connell N, Hong F, Peipert DJ, Gareen IF, Timsina LR, Gray R, Wagner LI, Carlos RC. Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients. Blood Cancer J. 2022 04 01; 12(4):53. PMID: 35365604; PMCID: PMC8975964.
    Citations:    Fields:    Translation:Humans
  6. Mansfield AS, Wei Z, Mehra R, Shaw AT, Lieu CH, Forde PM, Drilon AE, Mitchell EP, Wright JJ, Takebe N, Sharon E, Hovelson D, Tomlins S, Zeng J, Poorman K, Malik N, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. NPJ Precis Oncol. 2022 Mar 01; 6(1):13. PMID: 35233056; PMCID: PMC8888601.
    Citations: 1     
  7. Damodaran S, Zhao F, Deming DA, Mitchell EP, Wright JJ, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Suga JM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. J Clin Oncol. 2022 05 10; 40(14):1552-1561. PMID: 35133871; PMCID: PMC9084438.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  8. Krop IE, Jegede OA, Grilley-Olson JE, Lauring JD, Mitchell EP, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Kono SA, Ford JM, Garcia AA, Sui XD, Siegel RD, Slomovitz BM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO Precis Oncol. 2022 02; 6:e2100424. PMID: 35138919; PMCID: PMC8865530.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  9. Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart M, Roblin E, Michiels S. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. NPJ Breast Cancer. 2022 Jan 11; 8(1):3. PMID: 35017545; PMCID: PMC8752727.
    Citations: 2     
  10. Ip EH, Saldana S, Miller KD, Carlos RC, Gareen IF, Sparano JA, Graham N, Zhao F, Lee JW, O'Connell NS, Cella D, Peipert JD, Gray RJ, Wagner LI. Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events. Cancer. 2021 12 15; 127(24):4546-4556. PMID: 34726788; PMCID: PMC8887554.
    Citations:    Fields:    Translation:Humans
  11. Adams S, Othus M, Patel SP, Miller KD, Chugh R, Schuetze SM, Chamberlin MD, Haley BJ, Storniolo AMV, Reddy MP, Anderson SA, Zimmerman CT, O'Dea AP, Mirshahidi HR, Ahnert JR, Brescia FJ, Hahn O, Raymond JM, Biggs DD, Connolly RM, Sharon E, Korde LA, Gray RJ, Mayerson E, Plets M, Blanke CD, Chae YK, Kurzrock R. A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). Clin Cancer Res. 2022 01 15; 28(2):271-278. PMID: 34716198; PMCID: PMC8776596.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  12. Garcia SF, Gray RJ, Sparano JA, Tevaarwerk AJ, Carlos RC, Yanez B, Gareen IF, Whelan TJ, Sledge GW, Cella D, Wagner LI. Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. Cancer. 2022 Feb 01; 128(3):536-546. PMID: 34614209; PMCID: PMC8776586.
    Citations: 1     Fields:    Translation:Humans
  13. Bonkhoff AK, Xu T, Nelson A, Gray R, Jha A, Cardoso J, Ourselin S, Rees G, Jäger HR, Nachev P. Reclassifying stroke lesion anatomy. Cortex. 2021 12; 145:1-12. PMID: 34673291; PMCID: PMC8650827.
    Citations: 1     Fields:    Translation:Humans
  14. Yanez B, Gray RJ, Sparano JA, Carlos RC, Sadigh G, Garcia SF, Gareen IF, Whelan TJ, Sledge GW, Cella D, Wagner LI. Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Oncol. 2021 Jun 17. PMID: 34137783; PMCID: PMC8377561.
    Citations: 1     Fields:    
  15. Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]. Ann Oncol. 2021 Aug; 32(8):1068. PMID: 34099371; PMCID: PMC8929237.
    Citations:    Fields:    
  16. Albain KS, Gray RJ, Makower DF, Faghih A, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Wood WC, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW, Sparano JA. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. J Natl Cancer Inst. 2021 04 06; 113(4):390-399. PMID: 32986828; PMCID: PMC8599918.
    Citations: 11     Fields:    Translation:Humans
  17. Sadigh G, Gray RJ, Sparano JA, Yanez B, Garcia SF, Timsina LR, Sledge GW, Cella D, Wagner LI, Carlos RC. Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial. Cancer. 2021 07 15; 127(14):2545-2552. PMID: 33793979; PMCID: PMC8249352.
    Citations: 3     Fields:    Translation:Humans
  18. Sparano JA, Crager MR, Tang G, Gray RJ, Stemmer SM, Shak S. Reply to K. Ando et al. J Clin Oncol. 2021 06 10; 39(17):1947-1948. PMID: 33793318; PMCID: PMC8260921.
    Citations:    Fields:    
  19. Cleary JM, Wang V, Heist RS, Kopetz ES, Mitchell EP, Zwiebel JA, Kapner KS, Chen HX, Li S, Gray RJ, McShane LM, Rubinstein LV, Patton DR, Meric-Bernstam F, Dillmon MS, Williams PM, Hamilton SR, Conley BA, Aguirre AJ, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT. Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors. Clin Cancer Res. 2021 06 01; 27(11):2996-3004. PMID: 33637626; PMCID: PMC8542423.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  20. Kalinsky K, Hong F, McCourt CK, Sachdev JC, Mitchell EP, Zwiebel JA, Doyle LA, McShane LM, Li S, Gray RJ, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT. Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. JAMA Oncol. 2021 02 01; 7(2):271-278. PMID: 33377972; PMCID: PMC7774047.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  21. Sparano JA, Crager MR, Tang G, Gray RJ, Stemmer SM, Shak S. Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer. J Clin Oncol. 2021 02 20; 39(6):557-564. PMID: 33306425; PMCID: PMC8078482.
    Citations: 19     Fields:    Translation:Humans
  22. Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, Hamilton SR, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Harris LN, Takebe N, Sims DJ, Coffey B, Fu T, Routbort M, Zwiebel JA, Rubinstein LV, Little RF, Arteaga CL, Comis R, Abrams JS, O'Dwyer PJ, Conley BA. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020 11 20; 38(33):3883-3894. PMID: 33048619.
    Citations: 47     Fields:    Translation:HumansCTClinical Trials
  23. Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, Williams PM, Mitchell EP, Iafrate AJ, Sklar J, Harris LN, McShane LM, Rubinstein LV, Sims DJ, Routbort M, Coffey B, Fu T, Zwiebel JA, Little RF, Marinucci D, Catalano R, Magnan R, Kibbe W, Weil C, Tricoli JV, Alexander B, Kumar S, Schwartz GK, Meric-Bernstam F, Lih CJ, McCaskill-Stevens W, Caimi P, Takebe N, Datta V, Arteaga CL, Abrams JS, Comis R, O'Dwyer PJ, Conley BA. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst. 2020 10 01; 112(10):1021-1029. PMID: 31922567.
    Citations: 45     Fields:    Translation:HumansCTClinical Trials
  24. Salama AKS, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. J Clin Oncol. 2020 11 20; 38(33):3895-3904. PMID: 32758030.
    Citations: 18     Fields:    Translation:Humans
  25. Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. J Clin Oncol. 2020 07 20; 38(21):2407-2417. PMID: 32463741.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  26. Wagner LI, Gray RJ, Sparano JA, Whelan TJ, Garcia SF, Yanez B, Tevaarwerk AJ, Carlos RC, Albain KS, Olson JA, Goetz MP, Pritchard KI, Hayes DF, Geyer CE, Dees EC, McCaskill-Stevens WJ, Minasian LM, Sledge GW, Cella D. Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. J Clin Oncol. 2020 06 10; 38(17):1875-1886. PMID: 32271671.
    Citations: 16     Fields:    Translation:Humans
  27. Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE, Olson JA, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledge GW. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. JAMA Oncol. 2020 03 01; 6(3):367-374. PMID: 31566680.
    Citations: 36     Fields:    Translation:Humans
  28. Johnson DB, Zhao F, Noel M, Riely GJ, Mitchell EP, Wright JJ, Chen HX, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). Clin Cancer Res. 2020 04 15; 26(8):1812-1819. PMID: 31924734.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  29. Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol. 2019 Nov; 30(11):1821-1830. PMID: 31987089.
    Citations:    
  30. Azad NS, Gray RJ, Overman MJ, Schoenfeld JD, Mitchell EP, Zwiebel JA, Sharon E, Streicher H, Li S, McShane LM, Rubinstein L, Patton DR, Williams PM, Coffey B, Hamilton SR, Bahary N, Suga JM, Hatoum H, Abrams JS, Conley BA, Arteaga CL, Harris L, O'Dwyer PJ, Chen AP, Flaherty KT. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. J Clin Oncol. 2020 01 20; 38(3):214-222. PMID: 31765263; PMCID: PMC6968795.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  31. Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol. 2019 11 01; 30(11):1821-1830. PMID: 31504139; PMCID: PMC6927318.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  32. Korn EL, Gray RJ, Freidlin B. Noninferiority trials with nonadherence to the assigned randomized treatment. Clin Trials. 2019 12; 16(6):673-681. PMID: 31409130.
    Citations: 1     Fields:    Translation:Humans
  33. Dowling RJO, Kalinsky K, Hayes DF, Bidard FC, Cescon DW, Chandarlapaty S, Deasy JO, Dowsett M, Gray RJ, Henry NL, Meric-Bernstam F, Perlmutter J, Sledge GW, Bratman SV, Carey LA, Chang MC, DeMichele A, Ennis M, Jerzak KJ, Korde LA, Lohmann AE, Mamounas EP, Parulekar WR, Regan MM, Schramek D, Stambolic V, Thorat MA, Whelan TJ, Wolff AC, Woodgett JR, Sparano JA, Goodwin PJ. Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz050. PMID: 32337479; PMCID: PMC7049988.
    Citations: 6     Fields:    
  34. Dowling RJO, Sparano JA, Goodwin PJ, Bidard FC, Cescon DW, Chandarlapaty S, Deasy JO, Dowsett M, Gray RJ, Henry NL, Meric-Bernstam F, Perlmutter J, Sledge GW, Thorat MA, Bratman SV, Carey LA, Chang MC, DeMichele A, Ennis M, Jerzak KJ, Korde LA, Lohmann AE, Mamounas EP, Parulekar WR, Regan MM, Schramek D, Stambolic V, Whelan TJ, Wolff AC, Woodgett JR, Kalinsky K, Hayes DF. Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz049. PMID: 32337478; PMCID: PMC7050024.
    Citations: 6     Fields:    
  35. Jayasekera J, Sparano JA, Gray R, Isaacs C, Kurian A, O'Neill S, Schechter CB, Mandelblatt J. Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz062. PMID: 32337487; PMCID: PMC7049983.
    Citations: 1     Fields:    
  36. Sparano JA, Gray R. TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps. J Clin Oncol. 2019 07 20; 37(21):1841-1842. PMID: 31173552; PMCID: PMC6881095.
    Citations: 3     Fields:    Translation:Humans
  37. Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. N Engl J Med. 2019 06 20; 380(25):2395-2405. PMID: 31157962; PMCID: PMC6709671.
    Citations: 115     Fields:    Translation:Humans
  38. Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019 03 01; 37(7):559-569. PMID: 30650045; PMCID: PMC7010425.
    Citations: 195     Fields:    Translation:HumansCells
  39. Jayasekera J, Li Y, Schechter CB, Jagsi R, Song J, White J, Luta G, Chapman JW, Feuer EJ, Zellars RC, Stout N, Julian TB, Whelan T, Huang X, Shelley Hwang E, Hopkins JO, Sparano JA, Anderson SJ, Fyles AW, Gray R, Sauerbrei W, Mandelblatt J, Berry DA. Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1360-1369. PMID: 29718314; PMCID: PMC6292816.
    Citations: 9     Fields:    Translation:Humans
  40. Dahlberg SE, Gray RJ. Pragmatic approaches to address expansion cohort design. Cancer. 2018 08; 124(16):3290-3292. PMID: 29975413; PMCID: PMC6108919.
    Citations:    Fields:    Translation:Humans
  41. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):111-121. PMID: 29860917; PMCID: PMC6172658.
    Citations: 537     Fields:    Translation:Humans
  42. Yeruva SLH, Zhao F, Miller KD, Tevaarwerk AJ, Wagner LI, Gray RJ, Sparano JA, Connolly RM. E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ Breast Cancer. 2018; 4:1. PMID: 29354686.
    Citations: 30     
  43. Sparano JA, Gray R, Oktay MH, Entenberg D, Rohan T, Xue X, Donovan M, Peterson M, Shuber A, Hamilton DA, D'Alfonso T, Goldstein LJ, Gertler F, Davidson NE, Condeelis J, Jones J. A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. NPJ Breast Cancer. 2017; 3:42. PMID: 29138761.
    Citations: 26     
  44. Willis S, Sun Y, Abramovitz M, Fei T, Young B, Lin X, Ni M, Achua J, Regan MM, Gray KP, Gray R, Wang V, Long B, Kammler R, Sparano JA, Williams C, Goldstein LJ, Salgado R, Loi S, Pruneri G, Viale G, Brown M, Leyland-Jones B. High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. JCO Precis Oncol. 2017; 1. PMID: 32913979; PMCID: PMC7446538.
    Citations: 2     Fields:    
  45. Orbay JL, Gray R, Vernon LL, Sandilands SM, Martin AR, Vignolo SM. The EFCR Approach and the Radial Septum-Understanding the Anatomy and Improving Volar Exposure for Distal Radius Fractures: Imagine What You Could Do With an Extra Inch. Tech Hand Up Extrem Surg. 2016 Dec; 20(4):155-160. PMID: 27801774.
    Citations: 4     Fields:    Translation:Humans
  46. Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE. Reply to C. Shah et al. J Clin Oncol. 2016 05 20; 34(15):1824-5. PMID: 27001578.
    Citations:    Fields:    
  47. Li S, Gray RJ. Estimating treatment effect in a proportional hazards model in randomized clinical trials with all-or-nothing compliance. Biometrics. 2016 09; 72(3):742-50. PMID: 26799700.
    Citations: 4     Fields:    Translation:Humans
  48. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Perez EA, Olson JA, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015 Nov 19; 373(21):2005-14. PMID: 26412349; PMCID: PMC4701034.
    Citations: 444     Fields:    Translation:Humans
  49. Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. J Clin Oncol. 2015 Nov 20; 33(33):3938-44. PMID: 26371148.
    Citations: 66     Fields:    Translation:HumansCTClinical Trials
  50. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014 Sep 20; 32(27):2959-66. PMID: 25071121.
    Citations: 485     Fields:    Translation:HumansCells
  51. Gray RJ, Zujewski JA, Whelan TJ, Albain KS, Hayes D, Geyer CE, Dees EC, Perez EA, Keane MM, Vallejos Sologuren C, Goggins TF, Mayer IA, Brufsky A, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. J Clin Oncol. 2014 Sep 10; 32(26_suppl):36. PMID: 28141143.
    Citations:    
  52. Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Partridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014 Sep 09; 111(6):1241-8. PMID: 25117820.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  53. Freidlin B, Sun Z, Gray R, Korn EL. Reply to S. Goteti et al. J Clin Oncol. 2014 Mar 10; 32(8):856. PMID: 24493728.
    Citations:    Fields:    Translation:Humans
  54. Freidlin B, Korn EL, Gray R. Marker Sequential Test (MaST) design. Clin Trials. 2014 Feb; 11(1):19-27. PMID: 24085774.
    Citations: 14     Fields:    Translation:Humans
  55. Dodd LE, Korn EL, Freidlin B, Gu W, Abrams JS, Bushnell WD, Canetta R, Doroshow JH, Gray RJ, Sridhara R. An audit strategy for time-to-event outcomes measured with error: application to five randomized controlled trials in oncology. Clin Trials. 2013 Oct; 10(5):754-60. PMID: 23935162.
    Citations: 1     Fields:    Translation:Humans
  56. Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013 May 15; 105(10):701-10. PMID: 23641039.
    Citations: 146     Fields:    Translation:Humans
  57. Freidlin B, Sun Z, Gray R, Korn EL. Phase III clinical trials that integrate treatment and biomarker evaluation. J Clin Oncol. 2013 Sep 01; 31(25):3158-61. PMID: 23569306.
    Citations: 14     Fields:    Translation:Humans
  58. Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW, Sparano JA, Davidson NE, Badve SS. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013 Mar 01; 19(5):1281-9. PMID: 23340303.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  59. Hong F, Kahl BS, Gray R. Incremental value in outcome prediction with gene expression-based signatures in diffuse large B-cell lymphoma. Blood. 2013 Jan 03; 121(1):156-8. PMID: 23160463.
    Citations: 7     Fields:    Translation:HumansCells
  60. Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer. 2013 Mar 15; 119(6):1140-8. PMID: 23065954; PMCID: PMC3593800.
    Citations: 84     Fields:    Translation:Humans
  61. Sparano JA, Goldstein LJ, Davidson NE, Sledge GW, Gray R. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(2):751-7. PMID: 22706628.
    Citations: 7     Fields:    Translation:HumansCells
  62. Solin LJ, Gray R, Goldstein LJ, Recht A, Baehner FL, Shak S, Badve S, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW, Sparano JA. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat. 2012 Jul; 134(2):683-92. PMID: 22547108.
    Citations: 26     Fields:    Translation:HumansCells
  63. Kim HT, Gray R. Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials. Clin Trials. 2012 Apr; 9(2):155-63. PMID: 22353928.
    Citations: 4     Fields:    Translation:Humans
  64. McGhan LJ, Dueck AC, Gray RJ, Wasif N, McCullough AE, Pockaj BA. The changing landscape of axillary surgery: which breast cancer patients may still benefit from complete axillary lymph node dissection? J Surg Oncol. 2012 Sep 01; 106(3):254-9. PMID: 22034211.
    Citations:    Fields:    Translation:Humans
  65. McGhan LJ, Pockaj BA, Gray RJ, Bagaria SP, McLaughlin SA, Casey WJ, Rebecca AM, Wasif N. The impact of breast reconstruction on the decision to undergo contralateral prophylactic mastectomy. J Clin Oncol. 2011 Sep 20; 29(27_suppl):96. PMID: 27957925.
    Citations:    
  66. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW, Gray R. Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. Clin Cancer Res. 2011 Nov 15; 17(22):7194-203. PMID: 21933890.
    Citations: 13     Fields:    Translation:Humans
  67. Schroen AT, Petroni GR, Wang H, Thielen MJ, Sargent D, Benedetti JK, Cronin WM, Wickerham DL, Wang XF, Gray R, Cohn WF, Slingluff CL, Djulbegovic B. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clin Trials. 2011 Oct; 8(5):591-600. PMID: 21878447.
    Citations: 11     Fields:    Translation:Humans
  68. Tewari A, Grover S, Sooriakumaran P, Srivastava A, Rao S, Gupta A, Gray R, Leung R, Paduch DA. Nerve sparing can preserve orgasmic function in most men after robotic-assisted laparoscopic radical prostatectomy. BJU Int. 2012 Feb; 109(4):596-602. PMID: 21851544.
    Citations: 14     Fields:    Translation:Humans
  69. Manola JB, Gray RJ. When bad things happen to good studies. J Clin Oncol. 2011 Sep 10; 29(26):3497-9. PMID: 21844501.
    Citations:    Fields:    Translation:Humans
  70. McKenna P, Robinson AP, Neely D, Desjarlais MP, Carroll DC, Quinn MN, Yuan XH, Brenner CM, Burza M, Coury M, Gallegos P, Gray RJ, Lancaster KL, Li YT, Lin XX, Tresca O, Wahlström CG. Effect of lattice structure on energetic electron transport in solids irradiated by ultraintense laser pulses. Phys Rev Lett. 2011 May 06; 106(18):185004. PMID: 21635098.
    Citations: 1     Fields:    
  71. Dodd LE, Korn EL, Freidlin B, Gray R, Bhattacharya S. An audit strategy for progression-free survival. Biometrics. 2011 Sep; 67(3):1092-9. PMID: 21210772.
    Citations: 7     Fields:    Translation:Humans
  72. Brahmer JR, Dahlberg SE, Gray RJ, Schiller JH, Perry MC, Sandler A, Johnson DH. Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. J Thorac Oncol. 2011 Jan; 6(1):103-8. PMID: 21079521.
    Citations: 18     Fields:    Translation:HumansCTClinical Trials
  73. Rao RD, Cobleigh MA, Gray R, Graham ML, Norton L, Martino S, Budd GT, Ingle JN, Wood WC. Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group. Med Oncol. 2011 Dec; 28 Suppl 1:S39-47. PMID: 20878269.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  74. Gor PP, Su HI, Gray RJ, Gimotty PA, Horn M, Aplenc R, Vaughan WP, Tallman MS, Rebbeck TR, DeMichele A. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res. 2010; 12(3):R26. PMID: 20459744.
    Citations: 24     Fields:    Translation:Humans
  75. Wang R, Lagakos SW, Gray RJ. Testing and interval estimation for two-sample survival comparisons with small sample sizes and unequal censoring. Biostatistics. 2010 Oct; 11(4):676-92. PMID: 20439258.
    Citations: 11     Fields:    Translation:Humans
  76. Freidlin B, Korn EL, Gray R. A general inefficacy interim monitoring rule for randomized clinical trials. Clin Trials. 2010 Jun; 7(3):197-208. PMID: 20423925.
    Citations: 25     Fields:    Translation:Humans
  77. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW, Gray R. Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res. 2009 Dec 15; 15(24):7693-7700. PMID: 19996222.
    Citations: 12     Fields:    
  78. Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, Lowen MA, Ingle JN, Recht A, Wood WC. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009 Nov 10; 27(32):5319-24. PMID: 19826126.
    Citations: 74     Fields:    Translation:HumansCTClinical Trials
  79. Bhattacharya S, Fyfe G, Gray RJ, Sargent DJ. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. J Clin Oncol. 2009 Dec 10; 27(35):5958-64. PMID: 19826121.
    Citations: 11     Fields:    Translation:Humans
  80. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009 Oct 20; 27(30):4966-72. PMID: 19720913.
    Citations: 98     Fields:    Translation:HumansCTClinical Trials
  81. Agarwala SS, Gray RJ, Wong MK. Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma. J Clin Oncol. 2009 Sep 01; 27(25):e82-3; author reply e84. PMID: 19635995.
    Citations: 2     Fields:    Translation:Humans
  82. DeMichele A, Gray R, Horn M, Chen J, Aplenc R, Vaughan WP, Tallman MS. Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer Res. 2009 May 15; 69(10):4184-91. PMID: 19435922.
    Citations: 23     Fields:    Translation:HumansCells
  83. Ruan PK, Gray RJ. Analyses of cumulative incidence functions via non-parametric multiple imputation. Stat Med. 2008 Nov 29; 27(27):5709-24. PMID: 18712779.
    Citations: 19     Fields:    Translation:Humans
  84. Dahlberg SE, Gray RJ, Johnson BE. Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal. J Clin Oncol. 2008 Sep 10; 26(26):4233-5. PMID: 18779608.
    Citations: 1     Fields:    Translation:Humans
  85. Gray RJ. Weighted analyses for cohort sampling designs. Lifetime Data Anal. 2009 Mar; 15(1):24-40. PMID: 18712477.
    Citations: 30     Fields:    Translation:Humans
  86. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW, Perez EA, Shulman LN, Martino S, Sparano JA. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008 Sep 01; 26(25):4063-71. PMID: 18678838.
    Citations: 120     Fields:    Translation:HumansCTClinical Trials
  87. Freidlin B, Korn EL, Gray R, Martin A. Multi-arm clinical trials of new agents: some design considerations. Clin Cancer Res. 2008 Jul 15; 14(14):4368-71. PMID: 18628449.
    Citations: 49     Fields:    Translation:Humans
  88. Dilts DM, Sandler A, Cheng S, Crites J, Ferranti L, Wu A, Gray R, MacDonald J, Marinucci D, Comis R. Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group. Clin Cancer Res. 2008 Jun 01; 14(11):3427-33. PMID: 18519773.
    Citations: 27     Fields:    Translation:Humans
  89. Goldstein LJ, Gray RJ, Bugarini R, Shak S, Badve SS, Baehner FL, Davidson NE, Sledge GW, Sparano JA. Predictive utility of progesterone receptor (PR) and multigene expression in identifying benefit from adjuvant doxorubicin plus cyclophosphamide (AC) or docetaxel (AT) in intergroup trial E2197. J Clin Oncol. 2008 May 20; 26(15_suppl):557. PMID: 27948446.
    Citations:    
  90. Ruan PK, Gray RJ. Sensitivity analysis of progression-free survival with dependent withdrawal. Stat Med. 2008 Apr 15; 27(8):1180-98. PMID: 17768718.
    Citations: 2     Fields:    Translation:Humans
  91. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. Clin Cancer Res. 2008 Mar 01; 14(5):1407-12. PMID: 18316562.
    Citations: 106     Fields:    Translation:HumansCTClinical Trials
  92. Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008 Jan 01; 26(1):60-5. PMID: 18165641.
    Citations: 97     Fields:    Translation:Humans
  93. Freidlin B, Korn EL, George SL, Gray R. Randomized clinical trial design for assessing noninferiority when superiority is expected. J Clin Oncol. 2007 Nov 01; 25(31):5019-23. PMID: 17971602.
    Citations: 19     Fields:    Translation:Humans
  94. Freidlin B, Korn EL, Hunsberger S, Gray R, Saxman S, Zujewski JA. Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol. 2007 May 20; 25(15):2122-6. PMID: 17513819.
    Citations: 24     Fields:    Translation:Humans
  95. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007 May 20; 25(15):2127-32. PMID: 17513820.
    Citations: 320     Fields:    Translation:Humans
  96. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14; 355(24):2542-50. PMID: 17167137.
    Citations: 2017     Fields:    Translation:HumansCTClinical Trials
  97. Gray R. Bayesian modeling approach to examining heterogeneity in censored survival analysis. Biometrics. 2006 Jun; 62(2):623; author reply 623-4. PMID: 16918929.
    Citations: 2     Fields:    Translation:Humans
  98. Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, Carducci M, See W, Sweeney C, Liu G, Stein M, Dreicer R, Wilding G, DiPaola RS. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):1966-9. PMID: 16609005.
    Citations: 9     Fields:    Translation:Humans
  99. Ruan PK, Gray RJ. A method for analyzing disease-specific mortality with missing cause of death information. Lifetime Data Anal. 2006 Mar; 12(1):35-51. PMID: 16583298.
    Citations: 3     Fields:    Translation:Humans
  100. Lee ML, Gray RJ, Björkbacka H, Freeman MW. Generalized rank tests for replicated microarray data. Stat Appl Genet Mol Biol. 2005; 4:Article3. PMID: 16646848.
    Citations: 2     Fields:    
  101. Hughes LL, Gray RJ, Solin LJ, Robert NJ, Martino S, Tripathy D, Ingle JN, Wood WC. Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study. Cancer. 2004 Sep 01; 101(5):969-72. PMID: 15329905.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  102. Sparano JA, Gray R, Giantonio B, O'Dwyer P, Comis RL. Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Clin Cancer Res. 2004 Feb 15; 10(4):1206-11. PMID: 14977816.
    Citations: 11     Fields:    Translation:Humans
  103. Keller SM, Vangel MG, Wagner H, Schiller J, Herskovic A, Komaki R, Gray R, Marks RS, Perry MC, Livingston RB, Johnson DH. Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Lung Cancer. 2003 Oct; 42(1):79-86. PMID: 14512191.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  104. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003 Jul 03; 349(1):17-26. PMID: 12840088.
    Citations: 31     Fields:    Translation:HumansCTClinical Trials
  105. Gray RJ. Weighted estimating equations for linear regression analysis of clustered failure time data. Lifetime Data Anal. 2003 Jun; 9(2):123-38. PMID: 12735492.
    Citations: 1     Fields:    Translation:Humans
  106. Gray RJ, Li Y. Optimal weight functions for marginal proportional hazards analysis of clustered failure time data. Lifetime Data Anal. 2002 Mar; 8(1):5-19. PMID: 11878224.
    Citations: 5     Fields:    Translation:Humans
  107. Goldhirsch A, Gelber RD, Yothers G, Gray RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M, Coates AS. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr. 2001; (30):44-51. PMID: 11773291.
    Citations: 42     Fields:    Translation:Humans
  108. Gray RJ. Estimation of regression parameters and the hazard function in transformed linear survival models. Biometrics. 2000 Jun; 56(2):571-6. PMID: 10877318.
    Citations: 6     Fields:    Translation:Humans
  109. Gray RJ. On tests for group variation with a small to moderate number of groups. Lifetime Data Anal. 1998; 4(2):139-48. PMID: 9658772.
    Citations: 2     Fields:    Translation:Humans
  110. D'Ambra MN, Gray RJ, Hillman R, Jones JW, Kim HC, Rawitscher R, Schnaper H, Szymanski I, Vlahakes GJ, Kaplan D, Lynch KE, Guilfoyle M, Abels RI. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg. 1997 Dec; 64(6):1686-93. PMID: 9436556.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  111. Gray RJ. Spline-based tests in survival analysis. Biometrics. 1994 Sep; 50(3):640-52. PMID: 7981391.
    Citations: 27     Fields:    Translation:Humans
  112. Gray RJ. A Bayesian analysis of institutional effects in a multicenter cancer clinical trial. Biometrics. 1994 Mar; 50(1):244-53. PMID: 8086608.
    Citations: 19     Fields:    Translation:Humans
  113. Gray RJ. Some diagnostic methods for Cox regression models through hazard smoothing. Biometrics. 1990 Mar; 46(1):93-102. PMID: 2190638.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  114. Gray RJ, Tsiatis AA. A linear rank test for use when the main interest is in differences in cure rates. Biometrics. 1989 Sep; 45(3):899-904. PMID: 2790128.
    Citations: 32     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu).
Gray's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (269)
Explore
_
Co-Authors (25)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.